$39.25
-1.50[-3.68%]
At close: May 31
$39.25
0[0.00%]
After Hours: 5:04PM EDT
Apellis Pharmaceuticals
(NASDAQ:APLS)Apellis Pharmaceuticals Stock (NASDAQ:APLS), Analyst Ratings, Price Targets, Predictions
Apellis Pharmaceuticals Inc has a consensus price target of $74.9, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and Wells Fargo on May 31, 2024, May 28, 2024, and May 23, 2024. With an average price target of $62 between Piper Sandler, HC Wainwright & Co., and Wells Fargo, there's an implied 57.96% upside for Apellis Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Wells Fargo
Citigroup
UBS
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Apellis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 17.2% | Piper Sandler | Biren Amin | → $46 | Initiates | → Neutral | Get Alert |
| 05/28/2024 | Buy Now | 134.39% | HC Wainwright & Co. | Douglas Tsao | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 22.29% | Wells Fargo | Derek Archila | $57 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 52.87% | Citigroup | Yigal Nochomovitz | $67 → $60 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 134.39% | HC Wainwright & Co. | Douglas Tsao | → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 116.56% | UBS | Eliana Merle | $89 → $85 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 116.56% | Needham | Joseph Stringer | → $85 | Reiterates | Buy → Buy | Get Alert |
| 04/29/2024 | Buy Now | 32.48% | Mizuho | Graig Suvannavejh | $60 → $52 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | 134.39% | HC Wainwright & Co. | Douglas Tsao | → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 116.56% | Needham | Joseph Stringer | → $85 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 45.22% | Wedbush | Laura Chico | $67 → $57 | Maintains | Neutral | Get Alert |
| 04/15/2024 | Buy Now | 134.39% | HC Wainwright & Co. | Douglas Tsao | → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 116.56% | Needham | Joseph Stringer | → $85 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 52.87% | Mizuho | Graig Suvannavejh | $60 → $60 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | 101.27% | JP Morgan | Anupam Rama | $78 → $79 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | 126.75% | UBS | Eliana Merle | $87 → $89 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 134.39% | HC Wainwright & Co. | Douglas Tsao | → $92 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 70.7% | Wedbush | Laura Chico | $60 → $67 | Maintains | Neutral | Get Alert |
| 02/16/2024 | Buy Now | 52.87% | Mizuho | Graig Suvannavejh | $49 → $60 | Maintains | Neutral | Get Alert |
| 02/06/2024 | Buy Now | 106.37% | Baird | Colleen Kusy | → $81 | Reiterates | Outperform → Outperform | Get Alert |
| 02/05/2024 | Buy Now | 103.82% | Jefferies | Akash Tewari | $68 → $80 | Upgrade | Hold → Buy | Get Alert |
| 01/30/2024 | Buy Now | 101.27% | Oppenheimer | Justin Kim | $75 → $79 | Maintains | Outperform | Get Alert |
| 01/24/2024 | Buy Now | 91.08% | Needham | Joseph Stringer | $70 → $75 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | 106.37% | Baird | Colleen Kusy | $71 → $81 | Maintains | Outperform | Get Alert |
| 01/17/2024 | Buy Now | 134.39% | HC Wainwright & Co. | Douglas Tsao | $82 → $92 | Maintains | Buy | Get Alert |
| 01/12/2024 | Buy Now | 52.87% | Wedbush | Laura Chico | $39 → $60 | Maintains | Neutral | Get Alert |
| 01/11/2024 | Buy Now | 170.06% | Raymond James | Steven Seedhouse | $67 → $106 | Maintains | Strong Buy | Get Alert |
| 01/09/2024 | Buy Now | 129.3% | Goldman Sachs | Salveen Richter | $65 → $90 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 70.7% | Citigroup | Yigal Nochomovitz | $70 → $67 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 91.08% | Oppenheimer | Justin Kim | $88 → $75 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Apellis Pharmaceuticals (APLS)?
The latest price target for Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Piper Sandler on May 31, 2024. The analyst firm set a price target for $46.00 expecting APLS to rise to within 12 months (a possible 17.20% upside). 72 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?
The latest analyst rating for Apellis Pharmaceuticals (NASDAQ: APLS) was provided by Piper Sandler, and Apellis Pharmaceuticals initiated their neutral rating.
When was the last upgrade for Apellis Pharmaceuticals (APLS)?
The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.
When was the last downgrade for Apellis Pharmaceuticals (APLS)?
The last downgrade for Apellis Pharmaceuticals Inc happened on December 14, 2023 when Wells Fargo changed their price target from $67 to $54 for Apellis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?
While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a initiated with a price target of $0.00 to $46.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $39.25, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.